The activist investment firm Starboard Value has launched a proxy fight again Pfizer, questioning the company’s management ...

Barely three years since its coronavirus vaccine helped stem the pandemic, Pfizer’s stock has lost 50 percent of its value ...

Investors shrugged as Illumina pressed its case for building on its longtime leadership in next-generation sequencing, ...

Pfizer was riding high during the pandemic but has been overtaken by rivals including Eli Lilly and Novo Nordisk whose weight ...

Here are some of the major companies whose stocks moved on the week’s news.

Pfizer is facing a messy showdown this week after an outside bid to revive the company’s post-Covid share plunge took an ...

An errant email to Pfizer CEO Albert Bourla tipped off the executive to an activist investor campaign, Endpoints News’ Drew Armstrong and Max Bayer report. The Atlantic’s Nicholas Florko explores ...

Pfizer shares are on the up since US activist investor Starboard Value built up a stake in the drug maker. But strategic ...

Starboard Value alleged that Pfizer officials threatened legal action against two former top executives who had been working ...

JPMorgan Chase, Wells Fargo and BlackRock reported strong quarterly results to kick off earnings season, but concerns linger ...

Leerink Partners analyst David Risinger has maintained their neutral stance on PFE stock, giving a Hold rating on October 7. David ...

The ongoing corporate battle between Pfizer and activist investment firm Starboard Value escalated on Thursday when Starboard ...